Introduction {#sec1-1}
============

According to the World Health Organization (WHO), an adverse drug reaction (ADR) is defined as "a response to a drug that is noxious and unintended and occurs at doses, used in man for prophylaxis, diagnosis, or therapy of a disease or for modification of physiological function."\[[@ref1]\] Skin is one of the major target organs for ADRs. An adverse cutaneous drug reaction is an undesirable change in the structure or function of the skin, its appendages, or mucous membranes and it encompass all adverse events related to drug eruption, regardless of the etiology.\[[@ref2]\] The incidence of dermatological ADRs among indoor patients in developed countries ranges from 1--3%,\[[@ref3][@ref4]\] whereas in developing countries such as India, it is 2--5%.\[[@ref5]\] In many countries, ADRs rank among the top 10 leading causes of mortality and India is one of them.\[[@ref6]\] Drug eruptions are among the most common cutaneous disorders encountered by the dermatologist.\[[@ref2]\] There is a wide spectrum of cutaneous ADRs varying from transient maculopapular rash to toxic epidermal necrolysis.\[[@ref7]\]

Early detection, evaluation, and monitoring of ADRs are essential to reduce harm to the patients and thus improve public health. So the present study was undertaken to analyze the clinical spectrum of cutaneous ADRs and assess their seriousness, outcome, causality, severity, and preventability of the cutaneous ADRs.

Material and Methods {#sec1-2}
====================

A retrospective analysis was carried out at the Department of Pharmacology, BJ Medical College, a recognized Adverse Reaction Monitoring Center (AMC) and regional training center under the Pharmacovigilance Programme of India (PVPI). The suspected ADRs were diagnosed by treating consultants and relevant details of each ADR were collected in spontaneous ADR reporting form. Each ADR report was sent to the National Coordinating Center (NCC) via "Vigiflow." Details of each report were also simultaneously entered in the Microsoft Excel sheet. All cutaneous ADRs reported between January 2013 to May 2016 were identified from this database.

Data were analyzed to see the total number of ADR, clinical presentation of cutaneous ADRs, time relationship between the events, and the initiation of drug treatment. An analysis was also done to see the causal drug groups, suspected drugs and their routes of administration, other concomitant conditions, and the number of drugs prescribed i.e., polypharmacy. Causality assessment was done using the WHO--UMC scale and Naranjo\'s algorithm.\[[@ref8][@ref9]\] Severity was assessed using modified Hartwig and Seigel\[[@ref10]\] while preventability was assessed using modified Schumock and Thornton scale.\[[@ref11]\]

Results {#sec1-3}
=======

A total 2171 ADRs were reported between January 2013 to May 2016 at the Regional Adverse Drug Reaction Monitoring Center. Out of which total 538 (24.78%) were cutaneous ADRs.

The mean age of patients suffering from cutaneous ADRs was 33 ± 3 years and maximum no of cutaneous ADRs was reported in the age group of 18--35 years (46.28%) followed by 36--65 years (32.15%) and 1--12 years (10.59%). Men (55.2%) were more affected than women (44.8%).

 {#sec2-1}

### Clinical presentation of cutaneous ADRs {#sec3-1}

Different clinical presentations of cutaneous ADRs were observed. The most common was maculopapular rash (58.92%) followed by itching, burning of the skin (10.59%), and Stevens--Johnson syndrome (04.83%). Others cutaneous ADRs were alopecia, hyperpigmentation, injection site reaction, dryness of the skin and mucous membrane, photosensitivity reaction, hypersensitivity reaction, toxic epidermal necrolysis, fixed drug eruptions, and urticaria \[[Table 1](#T1){ref-type="table"}\].

###### 

Clinical presentation of cutaneous ADRs with their frequency

  Clinical presentation of cutaneous ADRs   Total no.   Frequency (%)
  ----------------------------------------- ----------- ---------------
  Maculopapular rash                        317         58.92
  Itching, burning, or redness              57          10.59
  Stevens--Johnson syndrome                 26          4.83
  Fixed drug eruption                       19          3.53
  Urticaria                                 19          3.53
  Alopecia                                  15          2.79
  Hyperpigmentation                         11          2.04
  Injection site reaction                   10          1.86
  Dryness of skin, mucous membrane          8           1.49
  Dermatitis                                6           1.12
  Vesiculobullous rash                      6           1.12
  Acneiform eruptions                       5           0.93
  Erythema multiforme                       4           0.74
  Photosensitivity reaction                 4           0.74
  Red discoloration of the skin             4           0.74
  Angioedema                                3           0.56
  Hirsutism                                 3           0.56
  Papular eruption                          3           0.56
  Thrombophlebitis                          3           0.56
  Vitiligo                                  3           0.56
  Hypersensitivity reaction                 2           0.37
  Toxic epidermal necrolysis                2           0.37
  Worsening of existing skin lesion         2           0.37
  Erythema nodosum                          1           3.13
  Hypopigmentation of skin                  1           0.19
  Ichthyosis on upper limb and lower limb   1           0.19
  Pallor and weakness                       1           0.19
  Redman syndrome                           1           0.19
  Swelling of the hand                      1           0.19
  Total                                     538         100

### Time relationship of cutaneous ADRs with drug treatment {#sec3-2}

Majority of the cutaneous ADRs were reported within 1 week of starting drug treatment. Amongst them, majority of the cutaneous ADRs were observed within 24 h of treatment (26.7%). However, cutaneous ADRs were also observed within 1 month to 1 year of treatment \[[Figure 1](#F1){ref-type="fig"}\].

![Time relationship of cutaneous ADRs with drug treatment (*n* = 538)](IJD-64-250d-g001){#F1}

The most common cutaneous ADRs reported within first 24 h were injection site reaction, angioedema, and rash, while thrombophlebitis, urticaria, and fixed drug eruption were seen within 1 week and Stevens--Johnson syndrome was observed within 1 month to 3 months of starting therapy. Interestingly, cutaneous ADRs like skin pigmentation, hair fall, and hirsutism were reported from 3--6 months of starting drug treatment \[[Figure 2](#F2){ref-type="fig"}\].

![Suspected drug groups causing cutaneous adverse drug reactions (*n* = 694). ARV: Antiretroviral, NSAIDs: Non-steroidal anti-inflammatory drugs. (\*Others: B lactams, cephalosporin, corticosteroid, B lactams + b lactamase inhibitor, blood products, antidepressant, sulfonamide + DHFR inhibitor, antiamoebic, antiacne, hematinics, antimalarial, anticholinergic, aminoglycosides, glycopeptide antibiotic, vaccine, antifungal, DMARDs, immunosuppressant, macrolides, NSAIDs + NSAIDs, unknown drug, vitamins/minerals, antiviral, fluoroquinolones + antiamoebic, antileprosy, anticancer, antidiabetic, lincosamides, sulfonamides, tetracycline, B blocker, antacid)](IJD-64-250d-g002){#F2}

### Causal drug groups {#sec3-3}

A total 694 drugs were responsible for 538 cutaneous ADRs. The most common causal drug groups were antimicrobials (45.72%) followed by NSAIDs (18.02%) and antiepileptics (9.66%). Among antimicrobial group, antiretroviral, antitubercular, and fluroquinolones were the most common causal drug groups \[[Table 2](#T2){ref-type="table"}\].

###### 

Details of clinical presentation of cutaneous ADRs (n=538)

  Duration               Adverse drug reactions
  ---------------------- -----------------------------------------------------------------------------------------
  \<24 h                 Maculopapular rash, injection site reaction, angioedema
  Upto 1 week            Fixed drug eruption, thrombophlebitis, dryness of skin, urticaria
  1 week to 4 weeks      Erythema multiforme, SJ syndrome, toxic epidermal necrolysis, photosensitivity reaction
  1 month to 3 months    SJ syndrome, hair fall, skin discoloration, fixed drug eruption
  3 months to 6 months   Skin pigmentation, hair fall, hirsutism
  6 months to 1 year     Rash, dryness of skin
  \>1 year               Rash

Surprisingly, the most common drugs causing cutaneous ADRs in NSAIDs group was paracetamol followed by diclofenac. In antimicrobial group, the most common suspected drugs were rifampicin followed by isoniazid, nevirapine, norfloxacin, ofloxacin, metronidazole, and fixed dose combinations like zidovudine + lamivudine + tenofovir and tenofovir + lamivudine + efavirenz.

### Outcome of cutaneous ADRs {#sec3-4}

Out of 538 cutaneous ADRs, 352 cutaneous ADRs were continuing at the time of reporting. While 62 were recovering and 93 had recovered. Unfortunately, six cutaneous ADRs recovered with sequels and one was fatal.

### Causality assessment, severity, and preventability {#sec3-5}

Majority of cutaneous ADRs were categorized as possible (54.61%) followed by probable (45.38%) as per the Naranjo\'s algorithm. While WHO--UMC causality assessment showed maximum possible relationship (65.56%) with drugs followed by probable (32.99%).

Majority of the cutaneous ADRs were moderately severe (378, 81.2%) while 90 were mild and 11 were severe in nature. Although majority of the cutaneous ADRs were not preventable (88.90%), 106 (11.10%) were preventable.

### Miscellaneous {#sec3-6}

Majority of the drugs were administered orally (79.10%) followed by injectable (13.54%) and topical (5.90%). Polypharmacy i.e., more than five drugs per patient was observed in 38 (7.06%) cases. However, majority of the cutaneous ADRs were non-serious (90.89%) in nature. While 34 patients required prolonged hospitalization, 4 patients required intervention to prevent permanent damage, 10 cutaneous ADRs were life-threatening, and 1 resulted in death due to Stevens--Johnson syndrome.

Discussion {#sec1-4}
==========

This study focused on the pattern of cutaneous ADRs reported at the regional ADR Monitoring Center. The reporting rate of cutaneous ADRs in our study was 24.78% with male preponderance. Maculopapular rash was most common clinical presentation and majority of cutaneous ADRs were reported within 1 week of starting therapy. The common causal drug group was antimicrobials followed by NSAIDs administered by oral route. Most of the cutaneous ADRs were non-serious and continuing at the time of reporting. A substantial number of cutaneous ADRs were mild in severity and not preventable.

The reporting rate of cutaneous ADRs was 24.78% in this study which is similar to study done by Ghosh *et al.* (25.8%).\[[@ref12]\] In our study male were more affected than female which was similar to the study of Sharma *et al.*\[[@ref13]\] However, in other studies females were commonly affected\[[@ref14]\] or both are equally affected.\[[@ref15]\] These differences may be due to different health care seeking patterns in various regions. In this study, cutaneous ADRs were most commonly found in the age group of 18--35 years followed by 36--65 years. Almost similar results were found in a study from a South Indian hospital, the majority of patients experiencing cutaneous ADRs were in the age group of 21--39 years followed by 40--60 years.\[[@ref16]\]

In the present study, commonest encountered cutaneous ADR was maculopapular rash followed by itching which is similar to a study done by Gohel *et al.*\[[@ref6]\] \[[Table 3](#T3){ref-type="table"}\] and Sushma *et al.*\[[@ref17]\] In other studies, fixed drug eruption, acneiform eruption, and urticaria were commonly encountered cutaneous ADRs.\[[@ref7]\] In our study, 26 cases of Stevens--Johnson syndrome were reported which was much higher than other studies.\[[@ref6][@ref18]\] As the study center is the Regional ADR Monitoring Center (AMC) recognized by the PVPI, training sessions were conducted for reporting of ADRs so there might be more awareness for reporting of ADRs among health care workers, and patients with serious ADRs were referred to our center from periphery which could be a reason for more cases of Stevens--Johnson syndrome. It developed mostly within 1 to 3 months of taking suspected medication, similar results were found by Patel *et al.*\[[@ref19]\] Other cutaneous ADRs developed within a week of taking suspected medication in the present study, similar results found by Hotchandani *et al.*\[[@ref20]\] This is because most of the skin reactions are immunological in nature and it emphasizes on close vigilance in the first week of starting therapy although few cutaneous ADRs developed after 6 months too.

###### 

Comparison of our study with similar other studies

                           Our study (2016)     Krishna *et al*.\[[@ref7]\] (2015)   Gohel *et al*.\[[@ref6]\] (2014)   Padmavathi *et al*.\[[@ref22]\] (2013)   Anjaneyan *et al*.\[[@ref18]\] (2013)
  ------------------------ -------------------- ------------------------------------ ---------------------------------- ---------------------------------------- ---------------------------------------
  Type of CADRS            1\. Rash             1\. Fixed drug eruptions             1\. Rash                           1\. Fixed drug eruption                  1\. Itching
  2\. Itching or burning   2\. Acne             2\. Pruritus                         2\. Maculopapular rash             2\. Rash                                 
  3\. SJ syndrome          3\. Urticaria        3\. Urticaria                        3\. Urticaria                      3\. Swelling                             
  Causal drug groups       1\. Antimicrobials   Not done                             1\. Antimicrobials                 1\. Antimicrobials                       1.Antimicrobials
  2\. NSAIDs               2\. NSAIDs           2\. NSAIDs                           2\. NSAIDs                                                                  
  3\. Antiepileptic        3\. Not mentioned    3\. Unknown                          3\. Antiepileptic                                                           
  Causality                                                                                                                                                      
  1\. WHO-UMC                                                                                                           Not done                                 21%
   ‑Possible               65.56%               17.4%                                54.64%                                                                      70%
   ‑ Probable              32.99%               52.4%                                36.08%                                                                      
  2\. Naranjo's score                                                                                                                                            
   ‑Possible               54.61%               Not done                             21.65%                             22%                                      Not done
   ‑Probable               45.38%               74.23%                               78%                                                                         
  Severity                                                                                                                                                       
   ‑Mild                   18.58%               30.4%                                2%                                 41.5%                                    Not done
   ‑Moderate               81.2%                65.3%                                98%                                58.5%                                    
   ‑Severe                 0.18%                4.3%                                 0                                  0                                        
  Preventability                                                                                                                                                 
   Definitely              --                   43.5%                                72.15%                             12.2%                                    Not done
   Probably                11.10%               30.4%                                27.84%                             --                                       
   Not preventable         88.90%               26.1%                                --                                 87.8%                                    

In our study, antimicrobials were the common causal drug group followed by NSAIDs and antiepileptics. Anjaneyan *et al.*\[[@ref18]\] study showed that antimicrobials, NSAIDs, and antiepileptic drugs were most prominent group of drugs responsible for cutaneous ADRs \[[Table 3](#T3){ref-type="table"}\]. Antimicrobial and NSAIDs are commonly prescribed by the physicians and general practitioners and sometimes irrationally used. Antimicrobials like antiretroviral and antitubercular drugs were more involved in developing cutaneous ADRs in the present study which was different finding from other studies.\[[@ref12]\] The integration of National Pharmacovigilance Program in Public Health Programs (Revised National Tuberculosis and Control Program and National AIDS Control Organization) has increased reporting of ADRs due to antitubercular and antiretroviral drugs. Paracetamol is commonest suspected drug causing cutaneous ADRs as in a study done by Gohel *et al.*

\[[@ref6]\] The reason behind this might be that paracetamol is most commonly prescribed concomitant medication. This is alarming as it is consumed as over-the-counter drug and generally considered as safe. We also observed polypharmacy in our study. It was one of the risk factor for developing cutaneous ADRs. Most of the cutaneous ADRs were non-serious in the present study. Similar results were found by Shah *et al.*\[[@ref21]\] and Gohel *et al.*\[[@ref6]\] As most of the cutaneous ADRs were rash and itching which can be managed without hospitalization.

In this study most common causality assessment was possible followed by probable in nature according to the Naranjo\'s and WHO--UMC criteria. But in other studies probable relationship is more than possible\[[@ref6][@ref7][@ref21][@ref22]\] \[[Table 3](#T3){ref-type="table"}\]. This may be due to use of combination drugs like antiretrovirals, antitubercular and to use of polypharmacy where assessment is difficult. Most of the cutaneous ADRs were moderately severe according to modified Hartwig and Seigel scale in the present study. Similar results were also reported by Padmavathi *et al.*\[[@ref22]\] This is because in most of the reactions we have to stop the suspected drug to prevent permanent damage. According to modified Schumock and Thorton scale most of the cutaneous ADRs were not preventable. This is also observed by other studies.\[[@ref12][@ref13]\] Possible reason for these is cutaneous ADRs are type B reactions and are immunological in nature.

 {#sec2-2}

### Limitations {#sec3-7}

The limitation of the study was that exact incidence of cutaneous ADRs could not be ascertained because it was spontaneous method of ADR reporting. Underreporting, lack of information about substituted drugs or treatment of ADRs, lack of information on recently introduced drugs, and single center were also other limitations of this study.

Conclusion {#sec1-5}
==========

The occurrence of cutaneous ADRs is common and they developed within 1 week of therapy. Antimicrobial agents and NSAIDs are the most common implicated drug class. Hence, physicians should closely monitor the patient in the first week while using such therapy for early detection and prevention of cutaneous ADRs.
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